MONROVIA, Calif., March 15, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present at the Oppenheimer 27th Annual Healthcare Conference...
↧